These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 22014750)
1. Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum. Grienke U; Mihály-Bison J; Schuster D; Afonyushkin T; Binder M; Guan SH; Cheng CR; Wolber G; Stuppner H; Guo DA; Bochkov VN; Rollinger JM Bioorg Med Chem; 2011 Nov; 19(22):6779-91. PubMed ID: 22014750 [TBL] [Abstract][Full Text] [Related]
2. Accessing biological actions of Ganoderma secondary metabolites by in silico profiling. Grienke U; Kaserer T; Pfluger F; Mair CE; Langer T; Schuster D; Rollinger JM Phytochemistry; 2015 Jun; 114():114-24. PubMed ID: 25457486 [TBL] [Abstract][Full Text] [Related]
3. [Chemical composition analysis of Ganoderma lucidum based on UPLC-Orbitrap-HRMS and virtual screening of FXR activators for treatment of liver fibrosis]. Zhang J; Li SY; Luo WH; Wang J; Beng SJ; Han HL; Xiong QP; Peng DY; Peng C Zhongguo Zhong Yao Za Zhi; 2024 Jul; 49(14):3804-3817. PubMed ID: 39099354 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease. Bharadwaj S; Lee KE; Dwivedi VD; Yadava U; Panwar A; Lucas SJ; Pandey A; Kang SG Sci Rep; 2019 Dec; 9(1):19059. PubMed ID: 31836806 [TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation. Schuster D; Markt P; Grienke U; Mihaly-Bison J; Binder M; Noha SM; Rollinger JM; Stuppner H; Bochkov VN; Wolber G Bioorg Med Chem; 2011 Dec; 19(23):7168-80. PubMed ID: 22018919 [TBL] [Abstract][Full Text] [Related]
7. Anticomplement activity of terpenoids from the spores of Ganoderma lucidum. Min BS; Gao JJ; Hattori M; Lee HK; Kim YH Planta Med; 2001 Dec; 67(9):811-4. PubMed ID: 11745016 [TBL] [Abstract][Full Text] [Related]
8. Triterpenes and Aromatic Meroterpenoids with Antioxidant Activity and Neuroprotective Effects from Wang C; Liu X; Lian C; Ke J; Liu J Molecules; 2019 Nov; 24(23):. PubMed ID: 31795252 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic lanostane-type triterpenoids from the fruiting bodies of Ganoderma lucidum and their structure-activity relationships. Chen S; Li X; Yong T; Wang Z; Su J; Jiao C; Xie Y; Yang BB Oncotarget; 2017 Feb; 8(6):10071-10084. PubMed ID: 28052025 [TBL] [Abstract][Full Text] [Related]
10. A new lanostane-type triterpene from the fruiting bodies of Ganoderma lucidum. Luo J; Zhao YY; Li ZB J Asian Nat Prod Res; 2002 Jun; 4(2):129-34. PubMed ID: 12067158 [TBL] [Abstract][Full Text] [Related]
11. Triterpenes from Alisma orientalis act as farnesoid X receptor agonists. Lin HR Bioorg Med Chem Lett; 2012 Jul; 22(14):4787-92. PubMed ID: 22683342 [TBL] [Abstract][Full Text] [Related]
12. Triterpenes from antler-shaped fruiting body of Ganoderma lucidum and their hepatoprotective activities. Shao H; Li Y; Wu C; Chen R; Kang J Phytochemistry; 2024 Aug; 224():114148. PubMed ID: 38763311 [TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and heme oxygenase-1 inducing activities of lanostane triterpenes isolated from mushroom Ganoderma lucidum in RAW264.7 cells. Choi S; Nguyen VT; Tae N; Lee S; Ryoo S; Min BS; Lee JH Toxicol Appl Pharmacol; 2014 Nov; 280(3):434-42. PubMed ID: 25239868 [TBL] [Abstract][Full Text] [Related]
14. Structure Identification and Anti-Cancer Pharmacological Prediction of Triterpenes from Ganoderma lucidum. Shao Y; Qiao L; Wu L; Sun X; Zhu D; Yang G; Zhang X; Mao X; Chen W; Liang W; Zhang Y; Zhang L Molecules; 2016 May; 21(5):. PubMed ID: 27213329 [TBL] [Abstract][Full Text] [Related]
15. Anti-androgen effects of extracts and compounds from Ganoderma lucidum. Liu J; Tamura S; Kurashiki K; Shimizu K; Noda K; Konishi F; Kumamoto S; Kondo R Chem Biodivers; 2009 Feb; 6(2):231-43. PubMed ID: 19235153 [TBL] [Abstract][Full Text] [Related]
16. Lanostane triterpenes from the fruiting bodies of Ganoderma lucidum and their inhibitory effects on adipocyte differentiation in 3T3-L1 Cells. Lee I; Seo J; Kim J; Kim H; Youn U; Lee J; Jung H; Na M; Hattori M; Min B; Bae K J Nat Prod; 2010 Feb; 73(2):172-6. PubMed ID: 20039640 [TBL] [Abstract][Full Text] [Related]
17. Steroids and triterpenes from the fruit bodies of Ganoderma lucidum and their anti-complement activity. Seo HW; Hung TM; Na M; Jung HJ; Kim JC; Choi JS; Kim JH; Lee HK; Lee I; Bae K; Hattori M; Min BS Arch Pharm Res; 2009 Nov; 32(11):1573-9. PubMed ID: 20091270 [TBL] [Abstract][Full Text] [Related]
18. Distinct Responses of Cytotoxic Ganoderma lucidum Triterpenoids in Human Carcinoma Cells. Ruan W; Wei Y; Popovich DG Phytother Res; 2015 Nov; 29(11):1744-52. PubMed ID: 26292672 [TBL] [Abstract][Full Text] [Related]
19. Lanostane-type triterpenoids from the mycelial mat of Ganoderma lucidum and their hepatoprotective activities. Zhang X; Gao X; Long G; Yang Y; Chen G; Hou G; Huo X; Jia J; Wang A; Hu G Phytochemistry; 2022 Jun; 198():113131. PubMed ID: 35248578 [TBL] [Abstract][Full Text] [Related]
20. [Anti-tumor target prediction and activity verification of Ganoderma lucidum triterpenoids]. Du GH; Wang HX; Yan Z; Liu LY; Chen RY Zhongguo Zhong Yao Za Zhi; 2017 Feb; 42(3):517-522. PubMed ID: 28952258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]